The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Long-term survivors with advanced nonsquamous non-small cell lung cancer (nsNSCLC) treated with first-line (1L) chemotherapy (CT) plus bevacizumab (B) and maintenance (mtc) B.
Javier de Castro
No relevant relationships to disclose
Dolores Isla
No relevant relationships to disclose
Jose Luis Gonzalez Larriba
No relevant relationships to disclose
Sergio Vazquez Estevez
No relevant relationships to disclose
Bartomeu Massuti
No relevant relationships to disclose
Jose Miguel Sanchez Torres
No relevant relationships to disclose
Manuel Domine
No relevant relationships to disclose
Antonio Calles
No relevant relationships to disclose
Jose Vicente Cardona
Employment or Leadership Position - Roche
Pilar Garrido López
No relevant relationships to disclose